1 rich Libsyn https://www.libsyn.com 90 600 The OCEAN Trial found that rivaroxaban did not significantly reduce the incidence of stroke, systemic embolism, or new covert embolic events compared with aspirin in patients at&amp;nbsp;high risk&amp;nbsp;for stroke who had undergone catheter ablation for atrial fibrillation&amp;nbsp;(AFib)&amp;nbsp;at least one year earlier. The central question—whether patients with a successful AFib ablation can safely&amp;nbsp;discontinue&amp;nbsp;anticoagulation—remains&amp;nbsp;unresolved. Overall, the trial reinforces the importance of individualized risk assessment rather than routine discontinuation of anticoagulation after ablation.&amp;nbsp; In this interview,&amp;nbsp;Thomas F. Deering MD, FACC&amp;nbsp;and&amp;nbsp;Atul&amp;nbsp;Verma, MD FACC&amp;nbsp;discuss&amp;nbsp;the&amp;nbsp;“OCEAN Trial: Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation”.&amp;nbsp; ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research http://accelaccorg.libsyn.com/website <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/40203495/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="90" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/content/198880300